Any feedback?
Please rate this page
(all_enzymes.php)
(0/150)

BRENDA support

1.14.14.1: unspecific monooxygenase

This is an abbreviated version!
For detailed information about unspecific monooxygenase, go to the full flat file.

Word Map on EC 1.14.14.1

Reaction

RH
+
[reduced NADPH-hemoprotein reductase]
 +
O2
=
ROH
 +
[oxidized NADPH-hemoprotein reductase]
 +
H2O

Synonyms

3AH15, 6 beta-hydroxylase, 6-beta-testosterone hydroxylase, 7-alkoxycoumarin O-dealkylase, 7-ethoxycoumarin-O-deethylase, 7-ethoxyresorufin-O-deethylase, AA omega-hydroxylase, Aldehyde oxygenase, Arachidonic acid epoxygenase, aromatase, aryl hydrocarbon hydroxylase, aryl-4-monooxygenase, BG04_163, BM3, BPH, Brain aromatase, class IV cytochrome P450 monooxygenase, clavine oxidase, CLOA, Clone PF26, Clone PF3/46, Coumarin 7-hydroxylase, CP2D6, Cyp, CYP monooxygenase, CYP102, CYP102 monooxygenase, CYP1027H1, CYP102A1, CYP102A2, CYP102A3, CYP102A7, CYP102B1, CYP106, CYP107, CYP1074A2, CYP109, CYP116B3, CYP116B4, CYP116B46, CYP134, CYP150A20, CYP152, CYP154H1, CYP19, CYP197, CYP1A, CYP1A1, CYP1A2, CYP1A3, CYP1B1, CYP24A1, CYP27A1, CYP28A5, CYP2A3, CYP2A6, CYP2B, CYP2B4, CYP2B6, CYP2C11, CYP2C19, CYP2C8, CYP2C9, CYP2D6, CYP2E1, CYP305A1, CYP3A, CYP3A1, CYP3A4, CYP3A5, CYP3A7, CYP4, CYP4502F4, CYP4A, CYP4A4, CYP4A6, CYP4A7, CYP4AA1, CYP4E2, CYP4F, CYP4F2, CYP4F3A, CYP4F3B, CYP5035A2, CYP5035A3, CYP5035A5, CYP5035C1, CYP5036A1, CYP5036A3, CYP5037B2, CYP505D1, CYP505D2, CYP505D3, CYP505D4, CYP51, CYP512B5, CYP512H1, CYP5136A2, CYP5136A3, CYP5136A5, CYP5139A1, CYP5141A1, CYP5141D1, CYP5142A3, CYP5142C1, CYP5144A3, CYP5144A7, CYP5144A9, CYP5144C7, CYP5144D4, CYP5145A3, CYP5147A1, CYP5150B1, CYP53A15, CYP53C2, CYP53D2, CYP5A1, CYP63A2, CYP6B1, CYP6B1v1, CYP6B1V1/CYP6B1V2/ CYP6B1V3, CYP6B3V1/CYP6B3V2, CYP6B4V1/CYP6B4V2, CYP6B5V1, CYP714D1, CYP82E2, CYP82E3, CYP82E4v1, CYP82E4v2, CYP8A1, CYP9F2, CYPIA1, CYPIA2, CYPIA4, CYPIA5, CYPIB1, CYPIIA1, CYPIIA10, CYPIIA11, CYPIIA12, CYPIIA13, CYPIIA2, CYPIIA3, CYPIIA4, CYPIIA5, CYPIIA6, CYPIIA7, CYPIIA8, CYPIIA9, CYPIIB1, CYPIIB10, CYPIIB11, CYPIIB12, CYPIIB19, CYPIIB2, CYPIIB20, CYPIIB3, CYPIIB4, CYPIIB5, CYPIIB6, CYPIIB9, CYPIIC1, CYPIIC10, CYPIIC11, CYPIIC12, CYPIIC13, CYPIIC14, CYPIIC15, CYPIIC16, CYPIIC17, CYPIIC18, CYPIIC19, CYPIIC2, CYPIIC20, CYPIIC21, CYPIIC22, CYPIIC23, CYPIIC24, CYPIIC25, CYPIIC26, CYPIIC27, CYPIIC28, CYPIIC29, CYPIIC3, CYPIIC30, CYPIIC31, CYPIIC37, CYPIIC38, CYPIIC39, CYPIIC4, CYPIIC40, CYPIIC41, CYPIIC42, CYPIIC5, CYPIIC6, CYPIIC7, CYPIIC8, CYPIIC9, CYPIID1, CYPIID10, CYPIID11, CYPIID14, CYPIID15, CYPIID16, CYPIID17, CYPIID18, CYPIID19, CYPIID2, CYPIID3, CYPIID4, CYPIID5, CYPIID6, CYPIID9, CYPIIE1, CYPIIF1, CYPIIF3, CYPIIF4, CYPIIG1, CYPIIH1, CYPIIH2, CYPIIIA1, CYPIIIA10, CYPIIIA11, CYPIIIA12, CYPIIIA13, CYPIIIA14, CYPIIIA15, CYPIIIA16, CYPIIIA17, CYPIIIA18, CYPIIIA19, CYPIIIA2, CYPIIIA21, CYPIIIA24, CYPIIIA25, CYPIIIA27, CYPIIIA28, CYPIIIA29, CYPIIIA3, CYPIIIA30, CYPIIIA31, CYPIIIA5, CYPIIIA6, CYPIIIA7, CYPIIIA8, CYPIIIA9, CYPIIJ1, CYPIIJ2, CYPIIJ3, CYPIIJ5, CYPIIJ6, CYPIIK1, CYPIIK3, CYPIIK4, CYPIIL1, CYPIIM1, CYPIVA4, CYPIVA8, CYPIVB1, CYPIVC1, CYPIVF1, CYPIVF11, CYPIVF12, CYPIVF4, CYPIVF5, CYPIVF6, CYPIVF8, CYPVIA1, CYPVIB1, CYPVIB2, CYPVIB4, CYPVIB5, CYPVIB6, CYPVIB7, CYPXIX, CYPXIXA1, CYPXIXA2, CYPXIXA3, Cyt P450, cytochrome P-450 4 enzyme, cytochrome P-450 BM3, cytochrome P-450 monooxygenase, cytochrome P450 2B4, cytochrome P450 3A, cytochrome P450 3A4, cytochrome P450 aromatase, cytochrome P450 BM3, cytochrome P450 monooxygenase, cytochrome P450 monooxygenase 116B3, cytochrome P450 monooxygenase 2A6, cytochrome P450 monooxygenase 2C8, cytochrome P450 monooxygenase 2C9, cytochrome P450 monooxygenase 3A4, cytochrome P450 monooxygenase pc-2, cytochrome P450 monooxygenase pc-4, cytochrome P450 monooxygenase pc-5, cytochrome P450 monooxygenase pc-6, cytochrome P450 monooxygenase PC-foxy1, cytochrome P450 oxidoreductase, cytochrome P450 reductase, Cytochrome P450-D2, cytochrome P450-dependent monooxygenase, cytochrome P450-dependent monooxygenase 1A2, cytochrome P450-monooxygenase, cytochrome-P450 hydroxylase, DAH1, DAH2, Debrisoquine 4-hydroxylase, EC 1.14.1.1, EC 1.14.14.2, EC 1.14.99.8, EC 1.99.1.1, ECOD, Ema, EROD, Estrogen synthetase, EUI, fatty acid hydroxylase, flavocytochrome P450BM-3, flavoprotein monooxygenase, flavoprotein-linked monooxygenase, FMO3, FraEuI1c_1415, FraEuI1c_2494, FraEuI1c_5334, GA 16a,17-epoxidase, GA-deactivating enzyme, Hepatic cytochrome P-450MC1, HLp, HMPREF1624_01477, IIA3, Isozyme 3A, Laurate omega-1 hydroxylase, Lauric acid omega-6-hydroxylase, liver cytochrome P450-dependent monooxygenase, LMC1, Mephenytoin 4-hydroxylase, MFO, microsomal monooxygenase, microsomal P-450, mixed function oxygenase, monooxygenase 3, monooxygenase P450 BM-3, More, N-demethylase, nicotine oxidase, O-demethylase, OLF2, Olfactive, Os05g0482400 protein, Ovarian aromatase, oxygenase, flavoprotein-linked mono-, P(3)450, P-448, P-450 PHPAH1, P-450(M-1), P-450-MK2, P-450AROM, P-450IB, P-450IIIAM1, P-450MC, P-450MP, P-450UT, P1-88, P24, P450, P450 17-alpha, P450 19A1, P450 1A1, P450 1A2, P450 1B1, P450 2A6, P450 2B6, P450 2C19, P450 2C9, P450 2D-29/2D-35, P450 2D6, P450 2E1, P450 2J2, P450 3A4, P450 4A11, P450 4F2, P450 BM3, P450 CM3A-10, P450 DUT2, P450 FA, P450 FI, P450 form 3B, P450 form HP1, P450 HSM1, P450 HSM2, P450 HSM3, P450 HSM4, P450 IIB1, P450 IIC2, P450 LM4, P450 LM6, P450 LMC2, P450 MD, P450 monooxygenase, P450 MP-12/MP-20, P450 P49, P450 PB1, P450 PB4, P450 PBC1, P450 PBC2, P450 PBC3, P450 PBC4, P450 PCHP3, P450 PCHP7, P450 TCDDAA, P450 TCDDAHH, P450 type B2, P450 types B0 and B1, P450(I), P450-11A, P450-15-alpha, P450-15-COH, P450-16-alpha, P450-254C, P450-3C, P450-6B/29C, P450-A3, P450-AFB, P450-ALC, P450-BM3, P450-CMF1A, P450-CMF1B, P450-CMF2, P450-CMF3, P450-DB1, P450-DB2, P450-DB3, P450-DB4, P450-DB5, P450-HFLA, P450-HP, P450-IIA10, P450-IIA11, P450-IIA3.1, P450-IIA3.2, P450-IIA4, P450-KP1, P450-LM2, P450-MC1, P450-MC4, P450-MK1, P450-MKJ1, P450-MKMP13, P450-MKNF2, P450-NMB, P450-OLF1, P450-OLF3, P450-P1, P450-P2/P450-P3, P450-P3, P450-PB1 and P450-PB2, P450-PCN1, P450-PCN2, P450-PCN3, P450-PM4, P450-PP1, P450-PROS2, P4501A1, P450arom, P450cam, P450CB, P450CMEF, P450E, P450EF, P450F, P450H, P450I, P450IIC5, P450MT2, P450RAP, P450RLM6, P450s 3A, P450SMO, P52, PB15, PHP2, PHP3, PikC, PikC hydroxylase, Progesterone 21-hydroxylase, Prostaglandin omega-hydroxylase, PTF1, PTF2, S-mephenytoin 4-hydroxylase, Sam5, sertraline N-demethylase, SIAM614_30676, Steroid hormones 7-alpha-hydroxylase, Testosterone 15-alpha-hydroxylase, Testosterone 16-alpha hydroxylase, Testosterone 6-beta-hydroxylase, Testosterone 7-alpha-hydroxylase, xenobiotic monooxygenase

ECTree

     1 Oxidoreductases
         1.14 Acting on paired donors, with incorporation or reduction of molecular oxygen
             1.14.14 With reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen into the other donor
                1.14.14.1 unspecific monooxygenase

Expression

Expression on EC 1.14.14.1 - unspecific monooxygenase

Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
EXPRESSION
ORGANISM
UNIPROT
LITERATURE
0.0001 mM dioxin treatment for 24, 48, and 72 h induces CYP1A1, CYP1A2 and CYP1B1 mRNA levels
-
beta-naphthoflavone (0.05 mM) causes a 71fold increase in CYP1A2-dependent activity and a 253fold increase in CYP1A2 mRNA expression in hepatocyte microsomes
beta-naphthoflavone (0.05 mM) causes a 9fold increase in CYP1A2-dependent activity and a 25fold increase in CYP1A2 mRNA expression in hepatocyte microsomes
dexamethasone (0.05 mM) and rifampicin (0.01 mM) increase CYP2C11 activity by a mean of 1.4fold in hepatocytes
dexamethasone (0.05 mM) and rifampicin (0.01 mM) increase CYP3A4 mRNA expression by a mean of 14fold in hepatocytes
dexamethasone (0.05 mM) increases CYP3A1 activity by a mean of 6fold and dexamethasone (0.05 mM) and rifampicin (0.01 mM) increase CYP3A1 mRNA expression by a mean of 167fold in hepatocytes
dexamethasone-mediated CYP3A induction
-
dietary methanol exposure increases gene expression of the genes CYP305A1, CYP9F2, CYP28A5, CYP4AA1, and CYP4E2
-
exposure to both 2,3,7,8-tetrachlorodibenzofuran and 2,3,4,7,8-pentachlorodibenzofuran results in dose-dependent increase of CYP1A2 mRNA due to an underlying aryl hydrocarbon receptor-mediated mechanism
Neogale vison
exposure to both 2,3,7,8-tetrachlorodibenzofuran and 2,3,4,7,8-pentachlorodibenzofuran results in dose-dependent increases of CYP1A1 mRNA and CYP1A protein levels due to an underlying aryl hydrocarbon receptor-mediated mechanism. Upregulation of CYP1A mRNA in liver is more consistent to the sum adipose 2,3,7,8-tetrachlorodibenzo-p-dioxin equivalent concentration than to the liver 2,3,7,8-tetrachlorodibenzo-p-dioxin equivalent concentration in minks treated with 2,3,7,8-tetrachlorodibenzofuran or 2,3,4,7,8-pentachlorodibenzofuran
Neogale vison
in hepatocyte cultures, treated with 0.05 mM Andrographis paniculata extract and Andrographolide, CYP2E1 is not significantly decreased (by 30%)
in hepatocyte cultures, treatment with 0.05 mM Andrographis paniculata extract and Andrographolide results in a 50% decrease in CYP3A1 expression and activity
in hepatocyte cultures, treatment with 0.05 mM Andrographis paniculata extract and Andrographolide results in a 60% decrease in CYP1A2 expression and activity
in hepatocyte cultures, treatment with 0.05 mM Andrographis paniculata extract and Andrographolide results in a 60% decrease in CYP2C11 expression and activity. After in vivo administration, Andrographis paniculata extract at dose levels of 0.5 g/kg/day (i.e. 5 mg/kg/day Andrographolide equivalents) and at 2.5 g/kg/day (i.e. 25 mg/kg/day Andrographolide equivalents) and Andrographolide at dose levels of 5 and 25 mg/kg/day significantly decrease CYP2C11 activity
in hepatocyte cultures, treatment with 0.05 mM Andrographis paniculata extract results in a slight decrease of CYP1A2 (30%) enzymatic activities
in hepatocyte cultures, treatment with 0.05 mM Andrographis paniculata extract results in a slight decrease of CYP2E1 (20%) enzymatic activities, whereas CYP2C9- and CYP3A4-dependent monooxygenase activities are significantly decreased by 40% and 60%, respectively. Andrographolide causes a 30% decrease in CYP2C9- and CYP3A4-dependent monooxygenase activities, which is not significant
mutations in NADPH-P450 reductase, identified in patients with disordered steroidogenesis/Antley-Bixler syndrome, reduce CYP3A4 activity. NADPH-P450 reductase mutants Y181D, A457H, Y459H, V492E and R616X loose more than 99% of CYP3A4 activity, while NADPH-P450 reductase mutations A287P, C569Y and V608F loose 60-85% activity
-
resveratrol inhibits dioxin-induced expression of CYP1A1, CYP1A2 and CYP1B1 by directly or indirectly inhibiting the recruitment of the transcription factors aryl hydrocarbon receptor and aryl hydrocarbon nuclear translocator to the xenobiotic response elements of the corresponding genes
-
significant induction of multiple P450 monooxygenase genes by nonylphenol in nutrient-rich malt extract cultures (2- to 195fold) or under defined low-nitrogen conditions (2- to 6fold)
some P450 genes are downregulated in nutrient-rich malt extract cultures (2.15- to 13.36fold) or in defined low-nitrogen cultures (2.02- to 4.15fold) in response to nonylphenol
V79-hCYP2E1-hSULT1A1 cells contain a higher level of hCYP2E1 protein than the parental V79-hCYP2E1 line (by a factor of 3–4)
-